Search clinical trials for: FMS-like tyrosine kinase receptor

Total 26083 results

Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Acute Myeloid Leukemia

Italy, Croatia, Estonia, Czechia, France, Spain, Sweden, Bulgaria, Lithuania, Serbia, Hungary, Finland, Norway, Romania, Slovakia
Novartis Pharmaceuticals

No longer available

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

FLT3-mutated Acute Myeloid Leukemia

Canada
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Advanced Solid Tumor

China
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
ONY
Avania

Not yet recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS (Aero-05)

Intubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
SCRI Development Innovations, LLC
Seagen Inc.

Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Breast Cancer

United States
Ohio State University

Recruiting

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

Treatment-resistant Schizophrenia

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Cabaletta Bio

Recruiting

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

MuSK Myasthenia Gravis

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
National Taiwan University Hospital

Recruiting

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

NSCLC Stage IV

Taiwan
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Neoplasms | Neoplasm Metastasis | Metastatic Gastrointestinal Carcinoid Tumor

United States, China
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Israel, Spain, Japan, France
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative Neoplasm

United States
QuantumLeap Healthcare Collaborative
M.D. Anderson Cancer Center; University of Colorado, Denver; University of Pennsylvania and other collaborators

Recruiting

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)

COVID-19

United States
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary, Argentina
University Health Network, Toronto
Bayer; AstraZeneca; Amgen; AnHeart Therapeutics Inc.; Applied Health Research Centre and other collaborators

Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (CARMA-BROS)

Cancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene Mutation

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

Liver Failure | Acute-On-Chronic Liver Failure | Liver Disease | Cirrhosis of the Liver

Switzerland, United Kingdom
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
Daiichi Sankyo, Inc.
Children's Oncology Group; Innovative Therapies For Children with Cancer Consortium

Recruiting

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Acute Myeloid Leukemia

United States, Spain, France, Israel, Denmark, Canada, Belgium, Italy, Netherlands, Sweden, United Kingdom
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
Dana-Farber Cancer Institute
AstraZeneca

Recruiting

Osimertinib In EGFR Mutant Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Hypereosinophilic Syndrome | Eosinophilic Myeloid Neoplasm

United States
AstraZeneca
Parexel

Active, not recruiting

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)

Non-small Cell Lung Cancer

Italy, Spain, United States, China, Germany, Israel
Janssen Research & Development, LLC

Active, not recruiting

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

Non-Small-Cell Lung Cancer

United States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada
QED Therapeutics, Inc.

Enrolling by invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Achondroplasia

United States, Spain, United Kingdom, France, Australia, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Bayer

Active, not recruiting

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)

Solid Tumors Harboring NTRK Fusion

United States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Bayer

Active, not recruiting

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)

Solid Tumors Harboring NTRK Fusion

United States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
Shanghai JMT-Bio Inc.

Active, not recruiting

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Local Advanced or Metastatic NSCLC | Harboring EGFR Common Mutation

China

Search clinical trials for: FMS-like tyrosine kinase receptor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations